StockData
Perspective Therapeutics, Inc. logo

Perspective Therapeutics, Inc. (CATX) stock

CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$0.75−0.03 (-3.85%)

Close on Nov 20, 2026Market cap $86.05MP/E –Yield –

Perspective Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Perspective Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $96.18M, up 72.2% year over year. For fiscal 2025 it was $84.22M, up 102.3% from the year before. Over ten years it grew 62.2% a year on average. The highest annual figure on record is $84.22M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$84.22M+102.3%
FY2024Dec 31, 2024$41.64M+4798.6%
FY2022Jun 30, 2022$850.00K-40.4%
FY2021Jun 30, 2021$1.43M+26.7%
FY2020Jun 30, 2020$1.13M-23.6%
FY2019Jun 30, 2019$1.47M-15.6%
FY2018Jun 30, 2018$1.75M+80.9%
FY2017Jun 30, 2017$965.00K+82.8%
FY2016Jun 30, 2016$528.00K-14.1%
FY2015Jun 30, 2015$615.00K-8.0%
FY2014Jun 30, 2014$668.80K+6.6%
FY2013Jun 30, 2013$627.11K-19.7%
FY2012Jun 30, 2012$780.58K-20.4%
FY2011Jun 30, 2011$981.19K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$21.54M+29.6%
Q1 FY2026CQ1 2026Mar 31, 2026$21.37M+49.1%
Q4 FY2025CQ4 2025Dec 31, 2025$32.92M+155.6%
Q3 FY2025CQ3 2025Sep 30, 2025$20.34M+69.1%
Q2 FY2025CQ2 2025Jun 30, 2025$16.62M+79.2%
Q1 FY2025CQ1 2025Mar 31, 2025$14.33M+92.3%
Q4 FY2024CQ4 2024Dec 31, 2024$12.88M+1518.5%
Q3 FY2024CQ3 2024Sep 30, 2024$12.03M+2090.9%
Q2 FY2024CQ2 2024Jun 30, 2024$9.28M+1633.6%
Q1 FY2024CQ1 2024Mar 31, 2024$7.45M+961.5%
Q4 FY2022CQ2 2022Jun 30, 2022$796.00K+70.1%
Q3 FY2022CQ1 2022Mar 31, 2022$549.00K+51.7%
Q2 FY2022CQ4 2021Dec 31, 2021$535.00K+87.7%
Q1 FY2022CQ3 2021Sep 30, 2021$702.00K+125.0%
Q4 FY2021CQ2 2021Jun 30, 2021$468.00K+45.3%
Q3 FY2021CQ1 2021Mar 31, 2021$362.00K+23.1%
Q2 FY2021CQ4 2020Dec 31, 2020$285.00K+2.9%
Q1 FY2021CQ3 2020Sep 30, 2020$312.00K+33.9%
Q4 FY2020CQ2 2020Jun 30, 2020$322.00K-5.6%
Q3 FY2020CQ1 2020Mar 31, 2020$294.00K-1.7%
Q2 FY2020CQ4 2019Dec 31, 2019$277.00K-33.1%
Q1 FY2020CQ3 2019Sep 30, 2019$233.00K-44.5%
Q4 FY2019CQ2 2019Jun 30, 2019$341.00K-40.4%
Q3 FY2019CQ1 2019Mar 31, 2019$299.00K-36.8%
Q2 FY2019CQ4 2018Dec 31, 2018$414.00K+21.8%
Q1 FY2019CQ3 2018Sep 30, 2018$420.00K+16.0%
Q4 FY2018CQ2 2018Jun 30, 2018$572.00K+81.0%
Q3 FY2018CQ1 2018Mar 31, 2018$473.00K+44.6%
Q2 FY2018CQ4 2017Dec 31, 2017$340.00K+126.7%
Q1 FY2018CQ3 2017Sep 30, 2017$362.00K+110.5%
Q4 FY2017CQ2 2017Jun 30, 2017$316.00K+121.0%
Q3 FY2017CQ1 2017Mar 31, 2017$327.00K+78.7%
Q2 FY2017CQ4 2016Dec 31, 2016$150.00K+158.6%
Q1 FY2017CQ3 2016Sep 30, 2016$172.00K+19.4%
Q4 FY2016CQ2 2016Jun 30, 2016$143.00K-8.5%
Q3 FY2016CQ1 2016Mar 31, 2016$183.00K+29.4%
Q2 FY2016CQ4 2015Dec 31, 2015$58.00K–
Q1 FY2016CQ3 2015Sep 30, 2015$144.00K–
Q4 FY2015CQ2 2015Jun 30, 2015$156.36K–
Q3 FY2015CQ1 2015Mar 31, 2015$141.40K–

More Perspective Therapeutics figures

See a number that looks wrong?